«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2018 01

Page:

49-52

Research Field:

Publishing date:

Info

Title:

Preventive effect of thaliadomide combined with palonosetron on nausea and vomiting induced by cisplatin chemotherapy in lung cancer patients

Author(s):

Chen Long¹; He Donglei²; Liang Dong¹; Lin Haifeng³; Feng Jun¹; Huang Ping⁴

1.Department of Medical Oncology，The Third People's Hospital of Hainan Province (Hainan Province Nongken Sanya Hospital)，Hainan Sanya 572000，China；2.The First Affiliated Hospital of Hainan Medical College，Hainan Haikou 570100，China；3.The Second Affiliated

Keywords:

thaliadomide; lung cancer; cisplatin; chemotherapy; vomiting

PACS:

R734.2

DOI:

10.3969/j.issn.1672-4992.2018.01.013

Abstract:

Objective：To evaluate the preventive efficacy of thaliadomide combined with palonosetron on nausea and vomiting induced by cisplatin chemotherapy in lung cancer patients.Methods：The clinical data of lung cancer patients，who received regimen of thaliadomide combined with palonosetron on nausea and vomiting induced by cisplatin chemotherapy between Jan 2015 and Jan 2016，were retrospectively reviewed.The efficacy and safety of thaliadomide combined with palonosetron was observed.Results：After four cycles of chemotherapy，the incidence of grade I-II nausea and vomiting in the experimental and control groups were 34.0%（17/50）and 54.3%（25/46），respectively（P=0.041）.The incidence of grade III-IV nausea and vomiting in the experimental and control groups were 2.0%（1/50）and 13.0%（6/46），the difference was also statistically significant（P=0.038）.After six cycles of chemotherapy，the incidence of grade I-II nausea and vomiting in the experimental and control groups were 43.8%（21/48）and 68.4%（26/38），respectively（P=0.018）.The incidence of grade III-IV nausea and vomiting in the experimental and control groups were 4.2%（2/48） and 18.4%（7/38），the difference was also statistically significant（P=0.033）.Conclusion：Thaliadomide combined with palonosetron is effective and well tolerated in lung cancer patients with nausea and vomiting induced by cisplatin based chemotherapy.Further clinical study is warranted.

References:

［1］Weigt J，Malfertheiner P.Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer［J］.Expert Rev Gastroenterol Hepatol，2010，4(4)：395-397.
［2］Li M，Gao EY.Clinical study of thalidomide combined with ondansetron in the prevention of nausea and vomiting in lung cancer patients with chemotherapy［J］.Modern Oncology，2016，24(17)：2719-2723.［李敏，高尔云.沙利度胺联合昂丹司琼预防肺癌化疗所致恶心呕吐的临床研究［J］.现代肿瘤医学，2016，24(17)：2719-2723.］
［3］Chang Q，Mao XL.Clinical study of Integrated Traditional and Western Medicine in the prevention of gastroenteric reaction by cisplatin［J］.Chinese Archives of Traditional Chinese Medicine，2007，25(5)：990-991.［常青，毛小玲．中西医结合防治顺铂所所致急性胃肠反应的临床研究［J］.中华中医药学刊,2007，25(5)：990-991.］
［4］Liu YP，Zhang J.Thalidomide improves prevention of chemotherapy-induced gastrointerstinal side effects following a modified FOLFOX7 regimen：results of a prospective randomized crossover study［J］.Tumori，2009，95(6)：691-696.
［5］Cui Y，Wang WY.The observation of treatment outcome of thalidomide combined with tropisetron in the treatment of vomiting by adjuvant chemotherapy in breast carcinoma［J］.The J Practical Medicine，2011，27(19)：3576-3578.［崔瑶，王文玉.沙利度胺联合托烷司琼治疗乳腺癌辅助化疗相关呕吐的疗效观察［J］.实用医学杂志,2011，27(19)：3576-3578.］
［6］Zuo CY.Clinical observation of treatment outcome of thalidomide combined with tropisetron hydrochloride in the prevention of nausea and vomiting by GP chemotherapy in MBC［J］.Chinese J Clinical Research，2014，27(12)：1491-1493.［左彩莹.沙利度胺联合盐酸托烷司琼对转移性乳腺癌GP方案化疗所致恶心呕吐的疗效观察［J］.中国临床研究，2014，27(12)：1491-1493.］
［7］Feng G，Chen HM，Hu P，et al.Clinical study of thalidomide in the prevention of delayed vomiting by cisplatin［J］.Chinese J Clinical Research，2015，28(10)：1329-1330.［封革，陈慧敏，胡萍，等.沙利度胺对顺铂所致迟发性呕吐的临床疗效观察［J］.中国临床研究，2015，28(10)：1329-1330.］
［8］Zhao Wei，Yu PY.Clinical observation of thalidomide in the treatment of delayed vomiting by chemotherapy［J］.Chin J Convalescent Med，2016，25(2)：201-202.
［9］Mori-Vogt S，Blazer M.Palonosetron for the prevention of chemotherapy induced nausea and vomiting［J］.Expert Rev Anticancer Ther，2013，13(8)：919-936.
［10］Roscoe JA，Heckler CE.Prevention of delayed nausea：A university of rochester cancer center community clinical oncology program study of patients receiving chemotherapy［J］.J Clin Oncol，2012，30(27)：3389-3395.
［11］Zhang Chi，Deng WY.Analysis of thalidomide in the quality of life of the malignant tumor patients treated with chemotherapy［J］.Elentron J Metah Nutr cancer，2015，2(3)：49-52.

Memo

Memo:

海南省自然科学基金(编号：814387)

Common functions

Last Update: 2017-11-30